Saccade latencies in TMS or no-TMS trials. by Antoni Valero-Cabre (159701)

“…Decreases in normalized AS latency differences suggest a TMS-induced acceleration of AS preparation time with regards to the observed effects for sham TMS (white columns) or active TMS (black columns) in a control site and vice-versa. …”

Neutrophil motility in healthy donors. by Kathryn L. Butler (244702)

“…Samples were rearranged in decreasing order of the average motilities. Bars represent standard error of the mean. …”

XAV939 has no effect on growth of cancer cells in optimal growth conditions. by Renyue Bao (121721)

“…Under these conditions 21H7 potently decreases growth of breast and colon cancer cells whereas XAV939 has no effect. …”

EGR1 prevents osteosarcoma cell migration into blood vessel in vivo. by Yukihiro Matsunoshita (232591)

“…The number of GFP- positive cells in blood was decreased in EGR1 -expressing 143B- inoculated mice (B) [error bars represent mean (SD)] (P<0.05). …”

Effect of long-term pancreas tissue slice culture under optimized conditions on exocrine tissue morphology and amylase expression. by Anja Marciniak (479504)

“…<p><i>(A)</i> Immunohistochemistry for amylase (red) and DAPI (blue) in lobules of freshly prepared and under optimized conditions cultured pancreas tissue slices. …”

<i>In vitro</i> cytoxicity of Tet-loaded nanoparticles and free Tet. by Rutian Li (203852)

“…</p><p>It can be noticed from the table that when the extracellular pH decreased from 7.4 to 6.8, the cytotoxicity of free Tet in all the tumor cell lines attenuated (which was evaluated by increase of IC50 values, P<0.05). …”

Effect of ECS on the dorsal HIP. by Antonia L. Dow (714490)

“…<p>(<b>a</b>) Repeated ECS increased the number of BrdU-labeled cells and decreased the number (mean ± SEM) of SPRY2-labeled cells within the DG (linear regression: <i>t</i>₈ = 3.41, <i>P</i><0.01); N = 5/group. …”

Effect of application of monomethyl fumarate in organotypic slice cultures of hippocampus after 30 min of OGD. by Oliver Althaus (19346776)

“…The cell viability increased and equally the rate of identified cell deaths decreased with increasing concentration of MMF. All Data are provided as mean ± SEM; ****p<0.0001 (one-way analysis of variance with Tukey’s multiple comparisons <i>post-hoc-test</i>); the number of samples per group is n = 3–5, with at least three independent preparations. …”

NFκB is necessary and sufficient to initiate pancreatic EMT. by Caitlin M. Braitsch (7010645)

“…(C, D) Anatabine also decreased mesenchymal VIM expression (asterisks). (E) The percent area covered by VIM⁺ pixels within the pancreatic epithelium (above a set threshold) was quantified in anatabine- and vehicle-treated <i>Lats1/2</i>^<i>PanKO</i> and WT explants. …”

Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis by Abiodun Ologunowa (21343002)

“…In the LDN group, the Standardized Mean Difference (SMD) for pain decreased by 1.03 (95% confidence interval (CI): −1.25, −0.80; I² = 25%), and fibromyalgia symptom severity decreased by 1.02 (95% CI: −1.35, −0.69; I² = 52%) post-LDN treatment compared to the baseline. …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”